Past issues are only available to subscribers. If you are not a member, click here to join.

JANUARY 2014PDF

Pancreatic Cancer

Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial

A phase III trial of Abraxane extended overall survival in metastatic pancreatic cancer, with some patients surviving longer than three years, when used in combination with gemcitabine. 

The updated OS data from the Metastatic Pancreatic Adenocarcinoma Clinical Trial was presented at the American Society of Clinical Oncology Gastrointestinal Conference in San Francisco. 

Leukemia
Phase III Trial of Imbruvica Halted, Following
Increases in Progression-Free Survival

A phase III study of Imbruvica in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma was stopped early following an interim analysis and at the recommendation of an independent data monitoring committee, which concluded the study demonstrated a significant difference in progression-free survival compared to ofatumumab.

Breast Cancer
Long-term Follow-up Shows ADH and ALH Tissue
Abnormalities Can Carry Similar Risk

Contrary to existing understanding, long-term follow-up of patients with two types of breast tissue abnormalities suggests that both types of abnormalities have the same potential to progress to breast cancer.

Kidney Cancer
Patients on Hypertension Meds Lived Longer, Analysis Shows
Liver Cancer
Post-Hoc Analysis of ThermoDox Suggests OS Improvement
Prostate Cancer
Study: Gene Assay Can Provide Valid Prognostic Information
Colon Cancer
Studies of Oncotype DX Test Presented at ASCO Symposium
Lung Cancer
MicroRNA Assay Detects Cancer Two Years Before LDCT in Study
NCI Approved Trials for the Month of January
FDA News

  • Accelerated Approval granted to Mekinist-Tafinlar combination in unresectable or metastatic melanoma

  • 510(k) Clearance granted to spectral breast density measurement application

  • Reagent system approved for prevention of graft-versus-host disease

  • FDA launches advisory committee membership nomination web portal
  • Orphan drug designation granted to BL-8040 as a treatment for stem cell mobilization
  • FDA lifts clinical hold on tosedostat
  • And more…
20140203 - Feb. 3, 2014
ISSUE 5 – JAN. 31, 2014PDF

Congress Mandates NIH Cut PR Costs, Coordinate Spending on Communications

Congressional appropriators instructed NIH to cut spending on communications activities and coordinate the broad range of activities that fall under the category of public relations.

The mandate is a part of the report that accompanied the recently passed appropriations bill.

photoIPRI’s Peter Boyle on Closing the Gap In Global Cancer Treatment and Outcomes

The International Prevention Research Institute has published “The State of Oncology 2013,” a report that highlights disparate cancer outcomes between higher- and lower-resource countries and proposes long-term recommendations. 

photoPresident Calls For Reversing Cuts to Basic Research Budget

In his state of the union address to Congress Jan. 28, President Barack Obama called for reversing the cuts made to basic research in the federal budget.

photoDrasga, Einhorn Make Appeal For Single-Payer Healthcare

In a feature article published in the Journal of Oncology Practice, oncologists Ray Drasga and Lawrence Einhorn called for their colleagues to endorse single-payer healthcare.

The journal is published by the American Society for Clinical Oncology.

photoACS, SU2C Commit $20 Million For Lung Cancer Dream Team

The American Cancer Society and Stand Up To Cancer announced a collaboration to fund translational research and advocacy programs.

photoIn Brief

  • Indiana University cancer center receives $15 million pledge from Vera Bradley Foundation

  • Hope Funds for Cancer Research announce James D. Watson Award 

  • Dept. of Defense offers $580 million in medical research funding

  • Justin Klamerus named chief quality officer at Karmanos Cancer Institute

  • Angela Davies named chief medical officer of Champions Oncology

  • UCSF and Quest Diagnostics form collaboration

  • John Porter to receive Public Welfare Medal from the National Academy of Sciences

photoFDA News

  • FDA lifts clinical hold on tosedostat

  • U.K. National Institute for Health and Care Excellence issues final opinion on Pixuvri

20140131 - Jan. 31, 2014
ISSUE 4 – JAN. 24, 2014PDF

Conversation with The Cancer Letter:
Seffrin To Retire After Restructuring ACS

The American Cancer Society has started a search to replace its chief executive officer, John Seffrin.

Seffrin, who became the CEO in 1992, recently completed streamlining of the society’s organizational structure, eliminating the autonomy of divisions, decreasing the number of board members, and making the century-old organization into a single corporate entity.

photoASCO, COA Present Plans For Cancer Care
Beyond the Fee-for-Service Pay Structure

The Community Oncology Alliance and the American Society of Clinical Oncology issued a joint statement on payment reform in cancer care and proposed alternative approaches to paying for cancer care. 

photoKomen Officials Say Charity is Stabilizing Despite 22 Percent Drop in Contributions

The Susan G. Komen Breast Cancer Foundation reported a 22 percent decline in contributions in fiscal 2013—totalling over $77 million—in recent financial statements.

Overall, the charity’s revenues fell by 18 percent from the 2012 fiscal year.

photoFDA News

  • Reagent system approved for the prevention of Graft-Versus-Host Disease

  • FDA launches advisory committee membership nomination web portal 

  • Orphan designation granted to BL-8040 for stem cell mobilization

  • EU CHMP issues positive opinion for Roche’s subcutaneous MabThera

20140124 - Jan. 24, 2014